Comparative Pharmacology
Head-to-head clinical analysis: ALTACE versus DEAPRIL ST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALTACE versus DEAPRIL ST.
ALTACE vs DEAPRIL-ST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiotensin-converting enzyme inhibitor; inhibits ACE, preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion.
Angiotensin-converting enzyme (ACE) inhibitor. Inhibits ACE, preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure.
2.5-5 mg orally once daily initially, titrated to 10-20 mg once daily; maximum 20 mg/day
Oral: 2.5 mg twice daily, titrated up to 5 mg twice daily as tolerated. Maximum dose: 10 mg daily.
None Documented
None Documented
Ramiprilat: 13–17 hours (prolonged in renal impairment, up to 50 hours in severe renal insufficiency; multiple doses: 45–60 hours effective half-life due to tissue binding)
8-10 hours; prolonged in renal impairment (up to 24 hours in severe cases)
Renal: 60% (30% as ramiprilat, 30% as metabolites); Fecal: 40% (unabsorbed drug and biliary metabolites)
Renal (90% as unchanged drug), biliary/fecal (10%)
Category C
Category C
ACE Inhibitor
ACE Inhibitor